Phytochemical Combination Therapy for Managing Diabetes-Associated Metabolic Dysfunction and Cognitive Decline.

Abstract

Diabetes mellitus is no longer viewed only as a disorder of glucose regulation. Long-standing hyperglycemia and insulin resistance set off a chain of oxidative stress, chronic inflammation and lipid disturbance that damages tissues well beyond the pancreas and the vasculature. Over the past decade, a growing body of evidence has shown that these same disturbances reach the brain, contributing to memory loss, slowed thinking and behavioral changes that are now commonly grouped under the heading of diabetes-associated cognitive decline. Because metabolic dysfunction and cognitive impairment in diabetes share overlapping molecular pathways, including AMPK, NF-κB, Nrf2, PI3K/Akt and acetylcholinesterase-related signaling, a therapy that can act on more than one of these targets at once has obvious appeal. This review brings together the current preclinical and early clinical evidence on curcumin and quercetin, two widely studied dietary phytochemicals, and examines the rationale for using them together rather than alone. Curcumin is best known for its anti-inflammatory and antioxidant activity, while quercetin has a stronger track record in improving insulin sensitivity and glucose handling. When combined, the two compounds appear to act in a complementary rather than overlapping manner, producing effects on glycemic control, oxidative markers and cognitive performance that are generally more consistent than either compound gives on its own. The review also looks at the practical barriers that have kept this approach from moving further into the clinic, particularly poor oral bioavailability, and discusses the delivery strategies, including phytosomes and nanoparticle systems, that are being tested to address this problem. The available data support combination phytochemical therapy as a promising, low-toxicity adjunct approach for diabetes-associated metabolic and cognitive dysfunction, though well-designed human trials with standardized dosing are still needed before firm clinical recommendations can be made.